Navigation Links
Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Date:7/9/2013

PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") a private biopharmaceutical company focused on developing new and innovative dermatological products and services announced that its Investigational New Drug (IND) Application to evaluate SIG990 in rosacea has been cleared by the U.S. Food and Drug Administration (FDA).

SIG990 is a safe topical treatment that addresses both erythema and inflammatory lesions and thus would be a significant and potentially better therapeutic option for rosacea patients then what is currently on the market. SIG990 is an isoprenylcysteine (IPC) analog that modulates toll-like receptor (TLR) and G-protein signaling demonstrating promising results in several in vitro cell based assays and efficacy in in vivo topical inflammatory animal models.

Instrumental in the pre-clinical development of SIG990 was funding from the National Institute of Allergy and Infectious Diseases (NIAID) via an SBIR grant. Dr. Eduardo Perez, VP of R&D and Business Development stated, "We thank NIAID for their support of this program. We would not have been able to perform the critical safety, pharmacology and manufacturing required without this grant support."

As a new chemical entity, SIG990 recently had composition of matter IP awarded (US Patent Application No. 12/566,839). Maxwell Stock, CEO of Dermalogix, commented, "We continue to make significant progress and are well-positioned to advance the development of our IPC compounds in dermatology. I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects."

About Signum Dermalogix
Signum Dermalogix, is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information pl
'/>"/>

SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Corporation today announced the release of,new data concerning ... was conducted by the Department of Physiology at,University ... agreement with Millipore was announced in 2006. ,The ... research &,development scientist for Millipore’s Bioprocess Division, in,a ...
... June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys,Genetics Inc. ... of,therapeutic proteins for metabolic and cardiovascular disease,today ... scientific poster and,abstract at the 67th Scientific ... Chicago. The Company's poster will disclose,recent accomplishments ...
Cached Medicine Technology:Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4SemBioSys to present new data at American Diabetes Association,annual meeting 2SemBioSys to present new data at American Diabetes Association,annual meeting 3
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... , WASHINGTON, Dec. 8 The National Business Group on ... employers, announced today that Sally Welborn, Senior Vice President of ... Directors, effective immediately. , "We are thrilled to announce Sally,s ... Senior Vice President of Human Resources at Coca-Cola Enterprises ...
... , ... Technologies, Inc. , has been selected by the Blue Cross ... watchlist screening software for OFAC, OIG and EPLS and USA PATRIOT ... compliance software to BCBSA,s Chicago headquarters and its member Blue Cross ...
... , - May Set Stage ... Dec. 8 Neurology researchers have shown that feeding amino acids ... stage for the first effective treatment for cognitive impairments suffered by ... animal model that dietary intervention can restore a proper balance of ...
... panic disorder, study finds , TUESDAY, Dec. 8 (HealthDay ... in their blood might be at increased risk for ... , Researchers analyzed information on 1,987 adults, aged 20 ... Health and Nutrition Examination Survey between 1997 and 2004. ...
... defined as the pathological retrograde movement of gastric ... which may be important in reflux are observed ... disorder in these patients is ineffective esophageal motility ... been shown to be strongly associated with isolated ...
... to a lack of suitable studies, it is unclear ... autologous haematopoietic stem cell transplantation. With this type of ... are removed at a convenient time and generally re-implanted ... is neither indication nor proof of additional benefit compared ...
Cached Medicine News:Health News:National Business Group on Health Elects Sally Welborn, Walmart Executive, to Board of Directors 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3Health News:With Amino Acid Diet, Mice Improve After Brain Injury 2Health News:With Amino Acid Diet, Mice Improve After Brain Injury 3Health News:Lead Exposure May Affect Mental Health 2Health News:Are manometric findings different between the patients with erosive and nonerosive disease? 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 2Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 3Health News:Autologous stem cell transplantation for soft tissue sarcoma: insufficient research into therapy 4
... 3 mirror lenses featuring ultra-clear Volk 3-Mirror ... 76°, 66° and 60°. The 3 ... well central and peripheral fundus viewing and ... angled to eliminate gaps in the visualized ...
... are a family of single-use direct view vitrectomy ... particular region of the retinal surface during eye ... 1 gram and is formed and polished to ... human cornea. Lenses come in boxes of 10 ...
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
... Prism are designed for midperipherical ... for tractional retinal detachments (PDR, ... detachment. They can be used ... midperipheral laser applications. Direct image ...
Medicine Products: